WARF: P07500US

  • Assigned to WARF as biological material.

Polyclonal Antibodies Against Equine Rhinitis A Virus 3AB, 3C and 3D Proteins


Ann Palmenberg, Svetlana Amineva, Aleksey Aminev

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in polyclonal antibodies against several equine rhinitis A virus proteins.
OVERVIEWEquine rhinitis A virus, formerly known as equine rhinovirus 1, causes a respiratory disease in horses similar to the common cold in humans. No vaccines against this virus are available commercially and no specific antiviral treatment exists.
THE INVENTIONUW-Madison researchers have developed polyclonal antibodies against recombinant proteins from equine rhinitis A virus. The antibodies can be used for specific molecular recognition of the equine rhinitis A virus proteins in vitro or in vivo using experimental techniques such as ELISA (enzyme linked immunosorbent assay), Western assays, protein immunoprecipitation (IP) and confocal fluorescence microscopy.
  • Studying equine rhinitis A virus proteins
  • May lead to new means of detecting, preventing and treating equine rhinitis A virus infection
  • All reagents have been tested for efficacy.
  • Most of the antibodies react with viral precursor proteins, in addition to the mature proteins against which they were raised.
For More Information About the Inventors
Related Technologies
  • For more antibodies identified by the inventors, see WARF reference numbers:
  • P07448US
  • P07499US
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.